Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism (for children under 1 year of age)

Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism (for children under 1 year of age)

Contact

 If you are interested in participating in the study or want to learn more, please get in touch. Contact us
This study is no longer recruiting.

Description
This study is arandomized, double-blind, placebo-controlled study that will evaluate thesafety and efficacy of dasiglucagon in children between the ages of 7 days and12 months who have congenital hyperinsulinism. Dasiglucagon will be given as asubcutaneous infusion while patients are admitted to the hospital. Othertreatments for hyperinsulinism may be changed as allowed while maintaining safeblood sugar levels. For the second part of the study, patients may be able togo home on the medication.

Eligibility and criteria
IRB Number:
18-014989
Clinical trial phase:
Phase II
Phase III
Official title:
A Randomized Trial in 2 parts: Double-Blind, Placebo-Controlled, Crossover Part 1 and Open-label Part 2, Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism

What to expect

Related specialties
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.